Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Leukemia 5Ovarian Neoplasms 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Precancerous Conditions 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Tongue Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Myeloproliferative Disorders 2

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × Microarray Analysis × Clear all
NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡